Zepbound and Wegovy represent two distinct pharmaceutical approaches to weight loss, though both rely on the same active ingredient: semaglutide. Understanding their differences helps patients and doctors choose the right option for individual health needs.
Semaglutide works by mimicking glucagon-like peptide-1, a hormone that regulates appetite and blood sugar. Both medications trigger the same biological mechanism, but they carry different FDA approvals and brand positioning.
Zepbound specifically received FDA approval for chronic weight management in adults with obesity or overweight with weight-related conditions. The drug targets weight loss as its primary therapeutic goal. Wegovy, also containing semaglutide, originally gained approval for type 2 diabetes management before becoming widely recognized for weight loss effects. Many physicians now prescribe Wegovy off-label for weight management.
Clinical trials demonstrate comparable efficacy between the two formulations. Patients using either medication typically lose 15 to 22 percent of body weight over 68 weeks, according to FDA data. Both require ongoing use. Weight typically returns when patients stop treatment.
Dosing protocols differ slightly. Both medications start at 0.25 milligrams weekly, with gradual increases over 16 to 20 weeks. Maximum maintenance doses reach 2.4 milligrams weekly for both drugs.
Side effects overlap significantly. Nausea, vomiting, and constipation occur commonly during initial treatment phases. Serious risks include pancreatitis, gallbladder problems, and thyroid concerns. Patients with personal or family histories of medullary thyroid cancer should avoid both medications.
Insurance coverage patterns diverge considerably. Zepbound often qualifies for coverage under obesity treatment policies, while Wegovy coverage depends on the diabetes indication. Out-of-pocket costs vary by plan and pharmacy.
The